Gabather AB has successfully completed the regulatory GLP toxicology studies with GT-002 in rodent and non-rodent animal models. The compound was generally safe and well tolerated in repeated dose administrations for 28 days in animals at dose levels that are expected to exceed a therapeutically relevant dose. Furthermore, safety pharmacology was without any remarks, and GT-002 showed no negative cardiovascular treatment-related effects, which are important safety features for further clinical development of GT-002.
"These results support moving forward into the clinic in the near future to assess safety and tolerability in healthy volunteers, says CEO Michel-Robin Witt"
For more information contact:
Michael-Robin Witt, VD Gabather
Gabather was founded in 2014 as a result of more than ten years of collaborative research between Lund University (Sweden) and the Research Institute of Biological Chemistry in Roskilde (Denmark). The aim of the company is to develop novel small molecule drugs to treat diseases with an origin in the central nervous system. Gabather founders are the Forskarpatent fund together with scientists Olov Sterner and Mogens Nielsen.Gabather is listed on Nasdaq First North and Erik Penser Bank are Certified Advisors for the company.
This is information that Gabather AB is required to publish under the EU Market Abuse Directive. The information was provided under the auspices of the above contact person for publication on July 3, 2018.